Fortress Biotech Analyst Ratings
Fortress Biotech Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 911.12% | Cantor Fitzgerald | → $5 | Reiterates | Overweight → Overweight |
| 05/16/2023 | 911.12% | Cantor Fitzgerald | $6 → $5 | Maintains | Overweight |
| 04/06/2023 | 911.12% | Benchmark | → $5 | Reiterates | → Speculative Buy |
| 08/04/2022 | 1113.35% | Ladenburg Thalmann | → $6 | Initiates Coverage On | → Buy |
| 07/14/2022 | 1113.35% | B. Riley Securities | $8 → $6 | Maintains | Buy |
| 04/20/2021 | 911.12% | Roth Capital | $4.5 → $5 | Maintains | Buy |
| 10/13/2020 | 860.57% | Roth Capital | $5 → $4.75 | Maintains | Buy |
| 10/12/2020 | 1922.25% | HC Wainwright & Co. | $11 → $10 | Maintains | Buy |
| 10/02/2020 | 1720.02% | Benchmark | → $9 | Initiates Coverage On | → Buy |
| 03/13/2020 | 1113.35% | B. Riley Securities | $9 → $6 | Maintains | Buy |
| 02/13/2020 | 1113.35% | Cantor Fitzgerald | → $6 | Initiates Coverage On | → Overweight |
| 12/18/2019 | 1720.02% | B. Riley Securities | → $9 | Initiates Coverage On | → Buy |
| 08/26/2019 | 3742.27% | Dawson James | → $19 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/15/2023 | 911.12% | 坎託·菲茨傑拉德 | → 5 美元 | 重申 | 超重 → 超重 |
| 05/16/2023 | 911.12% | 坎託·菲茨傑拉德 | 6 美元 → 5 美元 | 維護 | 超重 |
| 04/06/2023 | 911.12% | 基準 | → 5 美元 | 重申 | → 投機性買入 |
| 08/04/2022 | 1113.35% | 拉登堡塔爾曼 | → 6 美元 | 啓動覆蓋開啓 | → 購買 |
| 07/14/2022 | 1113.35% | B. 萊利證券 | 8 美元 → 6 美元 | 維護 | 購買 |
| 04/20/2021 | 911.12% | 羅斯資本 | 4.5 美元 → 5 美元 | 維護 | 購買 |
| 2020 年 10 月 13 日 | 860.57% | 羅斯資本 | 5 美元 → 4.75 美元 | 維護 | 購買 |
| 2020 年 12 月 10 日 | 1922.25% | HC Wainwright & Co. | 11 美元 → 10 美元 | 維護 | 購買 |
| 2020 年 2 月 10 日 | 1720.02% | 基準 | → 9 美元 | 啓動覆蓋開啓 | → 購買 |
| 03/13/2020 | 1113.35% | B. 萊利證券 | 9 美元 → 6 美元 | 維護 | 購買 |
| 02/13/2020 | 1113.35% | 坎託·菲茨傑拉德 | → 6 美元 | 啓動覆蓋開啓 | → 超重 |
| 12/18/2019 | 1720.02% | B. 萊利證券 | → 9 美元 | 啓動覆蓋開啓 | → 購買 |
| 08/26/2019 | 3742.27% | 道森·詹姆斯 | → 19 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Fortress Biotech (FBIO)?
豐澤生物科技（FBIO）的目標價格是多少？
The latest price target for Fortress Biotech (NASDAQ: FBIO) was reported by Cantor Fitzgerald on August 15, 2023. The analyst firm set a price target for $5.00 expecting FBIO to rise to within 12 months (a possible 911.12% upside). 3 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年8月15日公佈了豐澤生物科技（納斯達克股票代碼：FBIO）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計FBIO將在12個月內上漲至911.12％（可能上漲911.12％）。去年有3家分析公司公佈了評級。
What is the most recent analyst rating for Fortress Biotech (FBIO)?
豐澤生物科技（FBIO）的最新分析師評級是多少？
The latest analyst rating for Fortress Biotech (NASDAQ: FBIO) was provided by Cantor Fitzgerald, and Fortress Biotech reiterated their overweight rating.
豐澤生物科技（納斯達克股票代碼：FBIO）的最新分析師評級由坎託·菲茨傑拉德提供，豐澤生物科技重申了其增持評級。
When is the next analyst rating going to be posted or updated for Fortress Biotech (FBIO)?
豐澤生物科技（FBIO）的下一次分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fortress Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fortress Biotech was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與豐澤生物技術公司的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。豐澤生物科技的最新評級是在2023年8月15日提交的，因此你應該預計下一個評級將在2024年8月15日左右公佈。
Is the Analyst Rating Fortress Biotech (FBIO) correct?
分析師對豐澤生物科技（FBIO）的評級是否正確？
While ratings are subjective and will change, the latest Fortress Biotech (FBIO) rating was a reiterated with a price target of $0.00 to $5.00. The current price Fortress Biotech (FBIO) is trading at is $0.49, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的豐澤生物技術（FBIO）評級，目標股價爲0.00美元至5.00美元。豐澤生物科技（FBIO）目前的交易價格爲0.49美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。